In Conversation With ZS Experts: How to Compete When You’re Not the First or Best on the Market

Posted by Matilda Males on Mar 15, 2019 10:21:58 AM

Jennifer Curtis co-wrote this blog post with Matilda Males.

While customer experience is not a new concept in pharma, it has been relatively absent as a core strategy for many of the leading oncology companies. Why? Until recently, it hasn’t been necessary. Twenty years ago, the oncology market was dominated by a few key players whose success was driven by single blockbuster drugs that generated years of high returns. Today, the market has exploded. The combination of high unmet need and promising revenue potential has resulted in companies of all sizes dipping their toes into the oncology market. Fourteen of the largest pharma companies have one-third of their late-stage R&D focused exclusively on oncology, and almost 700 companies have one or more assets in late-stage development, according to IQVIA’s 2018 Global Oncology Trends report. We’re also seeing a decline in the duration of clinical trials and faster drug approvals, leading to shorter development life cycles. At the same time, there are fewer clinically differentiated assets that are competing within the same space and with high prices.


>
Read More

MACRA: A Stepping-Stone for Broader Changes

Posted by Christina Corridon on Dec 11, 2017 12:00:00 PM

Howard Deutsch co-wrote this blog post with Christina Corridon.

In its current form, the Medicare Access and CHIP (Children’s Health Insurance Program) Reauthorization Act (MACRA) of 2015 directly impacts the reimbursement rates and methodology of the physician fee schedule under Medicare Part B. However, MACRA is unlikely to have a significant impact on physician behavior or drug choice. Nonetheless, MACRA is part of a larger transition of payment based on volume to payment based on value (quality and cost reduction). Physicians will be penalized for continuing with “business as usual,” and newfound attention to tracking and reporting outcomes will be rewarded.


>
Read More

Oncology Biosimilars Outlook: How Key Stakeholders Can Plan for Change

Posted by ZS Editors on Jul 24, 2017 1:04:28 PM

With the oncology biosimilars market poised for expansion, ZS launched an effort to survey the landscape. Our 2017 Biosimilar Adoption Study polled 252 respondents—including 200 oncologists, 25 payers and 27 pharmacy directors—and the results provide a perspective on market perceptions and other factors that could drive or restrict oncology biosimilars’ adoption. 


>
Read More